KR950702420A - 알레르기 질환 치료를 위한 테르페나딘 대사물과 그것의 광학 순수 이성체(terfenadine metabolites and their optically pure isomers for treating allergic disorders) - Google Patents
알레르기 질환 치료를 위한 테르페나딘 대사물과 그것의 광학 순수 이성체(terfenadine metabolites and their optically pure isomers for treating allergic disorders) Download PDFInfo
- Publication number
- KR950702420A KR950702420A KR1019950700382A KR19950700382A KR950702420A KR 950702420 A KR950702420 A KR 950702420A KR 1019950700382 A KR1019950700382 A KR 1019950700382A KR 19950700382 A KR19950700382 A KR 19950700382A KR 950702420 A KR950702420 A KR 950702420A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- disease
- formula
- treatment
- asthma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
Claims (22)
- 구조식 I의 화합물로 구성된 제약학적 조성물에 있어서 :이때 Z는 COOH, COOCH3 또는 CH2OH 또는 이의 제약학적 수용가능한 염으로 어떠한 심장 부정맥을 유도하지 않는 항-히스타민 치료에 이용되는 것으로 사람에 구조식 I의 화합물의 치료요법적 효과량을 투여하는 것으로 구성되는 것을 특징으로 하는 조성물.
- 제1항에 있어서, 항-히스타민 치료는 알레르기성 질환, 천식, 코질환 또는 다른 당뇨병 연관된 소혈관질환, 운동설질환, 어지러움 또는 기침, 감기, 감기성 또는 인플루엔자 증상 그리고 불편함, 고통 열 그리고 일반적인 말라리아 관련 질환을 포함한 질환에 걸린 또는 걸림위험이 있는 사람의 치료방법인 것을 특징으로 하는 조성물.
- 제2항에 있어서, 알레르기성 질환은 천식 또는 알레르기성 비염인 것을 특징으로 하는 조성물.
- 진술한 어느 한항에 있어서, 항-히스타민 치료는 구조식 I의 조성물을 매일 1-500㎎ 적절하게는 20-200의 양으로 투여하는 것으로 구성된 것을 특징으로 하는 조성물.
- 제2항에 있어서, 치료는 천식 또는 코질환 또는 당뇨병과 연관된 또다른 소혈관 질환의 치료방법으로 치료에서 구조식 I의 조성물을 매일 0.01-500㎎ 적절하게는 0.01-200의 양으로 투여하는 것을 특징으로 하는 조성물.
- 진술한 어느 한항에 있어서, 제약학적으로 수용가능한 담체 또는 부형제로 구성된 것을 특징으로 하는 조성물.
- 진술한 어느 한항에 있어서, 비-스테로이드성 항-염증제 또는 비-나르코틴제의 치료요법적 효과량으로 구성된 것을 특징으로 하는 조성물.
- 제7항에 있어서, 구조식 I의 조성물은 20 내지 200㎎ 그리고 항-염증제 또는 무통제는 25 내지 600㎎으로 구성된 것을 특징으로 하는 조성물.
- 진술한 어느 한항에 있어서, 탈응혈제의 치료요법적 효과량으로 구성된 것을 특징으로 하는 조성물.
- 제9항에 있어서, 구조식 I의 조성물이 20 내지 200㎎ 그리고 탈응혈제는 5 내지 150㎎으로 구성된 것을 특징으로 하는 조성물.
- 전술한 어느 한 항에 있어서, 구조식 I의 조성물은 단일 광학적 이성질체이고, 다른 이성질체가 없는 것을 특징으로 하는 조성물.
- 제11항에 있어서, 구조식 I의 조성물은 메틸 R-(+)-4-[1-하이드록시-4-(4-하이드록시디페닐메틸-1-피페리디닐)부틸]-α,α-디메틸벤젠아세트산, R-(+)-4-[1-하이드록시-4-(4-하이드록시디페닐메틸-1-피페리디닐)부틸]-α,α-디메틸벤젠아세트산 그리고 R-(+)-1-[p-(2-하이드록시메틸프로프-2-일) 페닐]-4-[4-α-하이드록시-α-페닐벤질)피페르딘-1-일)부탄올과 이의 제약학적 수용 가능한 염에서 선택되고, 조성물은 선택된 조성물의 S 이설질체는 없는 것을 특징으로 하는 조성물.
- 제11항에 있어서, 구조식 I의 조성물은 메틸 S-(-)-4[1-하이드록시-4-(4-하이드록시디페닐매틸-1-피페르디닐)부틸]-α, α-디메틸벤젠아세트산, S-(-)-4-[1-하이드록시-4-(4-하이드록시디페닐매틸-1-피페리디닐)부틸]-α,α-디메틸벤젠아세트산 그리고 S-(-)-1-[p-(2-하이드록시메틸프로프-2-일) 페닐]-4[4-(α-하이드록시-α-페닐벤질)피페르딘-1-일) 부탄올과 이의 제약학적 수용 가능한 염에서 선택되고, 조성물은 선택된 조성물의 R 이성질체는 없는 것을 특징으로 하는 조성물.
- 제12항에 있어서, 구조식 I의 조성물이 90 중량% 이상의 R-이성질체로 구성되는 것을 특징으로 하는 조성물.
- 제13항에 있어서, 구조식 I의 조성물이 90 중량% 이상의 S-이성질체로 구성되는 것을 특징으로 하는 조성물.
- 전술한 어느 한 항에 있어서, Z는 COOH이고 구조식 I의 조성물은 테르페나딘 카르복실레이트인 것을 특징으로 하는 조성물.
- 환자에게 어떠한 심각한 심장부정맥을 유도하지 않고 항-히스타민 치료를 제공하는 방법에 있어서 환자에게 전술 1-16항에 따른 제약학적 조성물을 치료요법적 효과량으로 투여하는 것을 특징으로 하는 방법.
- 제17항에 있어서, 치료는 알레르기성 질환, 천식, 코질환 또는 다른 당뇨병 연관된 소혈관질환, 운동성질환, 어지러움 또는 기침, 감기, 감기성 또는 인플루엔자 증상 그리고 불편함, 고통 열 그리고 일반적인 말라리아 관련 질환을 포함하는 질병에 걸린 또는 걸릴염려가 있는 사람의 치료방법인 것을 특징으로 하는 방법.
- 제18항에 있어서, 알레르기성 질환은 천식 또는 알레르기성 비염인 것을 특징으로 하는 방법.
- 제1 내지 16항에 따른 조성물의 용도에 있어서, 어떠한 심각한 심장 부정맥을 유도하지 않고 사람에게 구조식 I의 화합물의 치료요법적 효과량을 투여하는 것으로 구성된 항-히스타민 치료에 이용되는 약물을 제조하기 위한 것을 특징으로 하는 용도.
- 제20항에 있어서, 치료는 알레르기성 질환, 천식, 코질환 또는 다른 당뇨병 연관된 소혈관질환, 운동성질환, 어지러움 또는 기침, 감기, 감기성 또는 인플루엔자 증상 그리고 불편함, 고통 열 그리고 일반적인 말라리아 관련 질환을 포함하는 질병에 걸린 또는 걸릴 위험이 있는 사람의 치료방법인 것을 특징으로 하는 용도.
- 제24항에 있어서, 알레르기성 질환은 천식 또는 알레르기성 비염인 것을 특징으로 하는 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92415692A | 1992-08-03 | 1992-08-03 | |
US92418292A | 1992-08-03 | 1992-08-03 | |
US07/924156 | 1992-08-03 | ||
US07/924182 | 1992-08-03 | ||
PCT/US1993/007260 WO1994003170A1 (en) | 1992-08-03 | 1993-08-03 | Terfenadine metabolites and their optically pure isomers for treating allergic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
KR950702420A true KR950702420A (ko) | 1995-07-29 |
Family
ID=27129882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950700382A KR950702420A (ko) | 1992-08-03 | 1993-08-03 | 알레르기 질환 치료를 위한 테르페나딘 대사물과 그것의 광학 순수 이성체(terfenadine metabolites and their optically pure isomers for treating allergic disorders) |
Country Status (24)
Country | Link |
---|---|
US (1) | US5375693A (ko) |
EP (4) | EP0815860B1 (ko) |
JP (6) | JP3041954B2 (ko) |
KR (1) | KR950702420A (ko) |
AT (3) | ATE322899T1 (ko) |
AU (3) | AU675240B2 (ko) |
BR (1) | BR9306841A (ko) |
CA (1) | CA2141572C (ko) |
CZ (1) | CZ27495A3 (ko) |
DE (5) | DE9320925U1 (ko) |
DK (3) | DK0701443T4 (ko) |
ES (3) | ES2257757T3 (ko) |
FI (1) | FI950467A (ko) |
GB (1) | GB2284351B (ko) |
GR (3) | GR960300024T1 (ko) |
HK (1) | HK1045806B (ko) |
HU (1) | HU226242B1 (ko) |
NO (1) | NO310644B1 (ko) |
PL (1) | PL174373B1 (ko) |
PT (2) | PT1214937E (ko) |
RO (1) | RO116043B1 (ko) |
RU (1) | RU2167657C2 (ko) |
SK (1) | SK12495A3 (ko) |
WO (1) | WO1994003170A1 (ko) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69320952T2 (de) * | 1992-05-11 | 1999-05-27 | Merrell Pharma Inc | Verwendung von terfenadin-derivaten als antihistaminika in leberkranken patienten |
HU226242B1 (en) * | 1992-08-03 | 2008-07-28 | Sepracor Inc | Use of terfenadin carboxylic acid, their salt and optically pure isomers for the preparation of pharmaceutical compositions, and pharmaceutical compositions against allergic disorders |
US20020007068A1 (en) | 1999-07-16 | 2002-01-17 | D'ambra Thomas E. | Piperidine derivatives and process for their production |
DE69433346T2 (de) * | 1993-06-24 | 2004-09-09 | Albany Molecular Research, Inc. | Herstellung von Verbindungen, die in der Produktion von Piperidin-Derivaten nützlich sind |
WO1995010278A1 (en) * | 1993-10-15 | 1995-04-20 | Hoechst Marion Roussel, Inc. | Treatment of allergic disorders with terfenadine carboxylate |
US20030045722A1 (en) * | 1994-05-18 | 2003-03-06 | Henton Daniel R. | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof |
CA2189007C (en) | 1994-05-18 | 2004-03-02 | Daniel R. Henton | Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof |
US5455049A (en) * | 1995-01-04 | 1995-10-03 | Ascent Pharmaceuticals, Inc. | Terfenadine oral powder |
ATE226819T1 (de) * | 1995-02-28 | 2002-11-15 | Aventis Pharma Inc | Arzneizubereitungen für piperidinalkanolderivate |
GB9513972D0 (en) * | 1995-07-08 | 1995-09-06 | Merck Sharp & Dohme | Pharmaceutical compositions |
US5906747A (en) * | 1995-11-13 | 1999-05-25 | Biosepra Inc. | Separation of molecules from dilute solutions using composite chromatography media having high dynamic sorptive capacity at high flow rates |
US6355656B1 (en) | 1995-12-04 | 2002-03-12 | Celgene Corporation | Phenidate drug formulations having diminished abuse potential |
US5733756A (en) * | 1996-01-05 | 1998-03-31 | Celgene Corporation | Lactams and processes for stereoselective enrichment of lactams, amides, and esters |
US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
US5908850A (en) * | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US6201124B1 (en) | 1995-12-21 | 2001-03-13 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
US6153754A (en) | 1995-12-21 | 2000-11-28 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
ES2124167B1 (es) * | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | Nuevos derivados del bencimidazol con actividad antihistaminica. |
US5925761A (en) * | 1997-02-04 | 1999-07-20 | Sepracor Inc. | Synthesis of terfenadine and derivatives |
US6962997B1 (en) * | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
TR200000517T2 (tr) * | 1997-08-26 | 2000-08-21 | Hoechst Marion Roussel, Inc. | Piperidinoalkanol-Konjesyon azaltıcıdan oluşan kombinasyona yönelik farmasötik kompozisyon. |
US6194431B1 (en) | 1998-04-14 | 2001-02-27 | Paul D. Rubin | Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
DE19913862C2 (de) * | 1999-03-26 | 2003-04-10 | Forschungszentrum Juelich Gmbh | Verfahren zur biokatalysierten Umsetzung schlecht wasserlöslicher Substanzen |
DE10007203A1 (de) * | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
US6613907B2 (en) | 2000-11-08 | 2003-09-02 | Amr Technology, Inc. | Process for the production of piperidine derivatives with microorganisms |
PL366576A1 (en) * | 2001-04-09 | 2005-02-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of fexofenadine hydrochloride |
US20030021849A1 (en) * | 2001-04-09 | 2003-01-30 | Ben-Zion Dolitzky | Polymorphs of fexofenadine hydrochloride |
WO2003020274A1 (en) * | 2001-08-30 | 2003-03-13 | Aventis Pharmaceuticals Inc. | Treatment of atopic dermatitis |
EP1474392A1 (en) * | 2002-06-10 | 2004-11-10 | Teva Pharmaceutical Industries Ltd. | Polymorphic form xvi of fexofenadine hydrochloride |
US20050026890A1 (en) * | 2003-07-31 | 2005-02-03 | Robinson Cynthia B. | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
JP4515121B2 (ja) | 2004-03-15 | 2010-07-28 | 東芝テック株式会社 | ワイヤドットプリンタヘッド及びワイヤドットプリンタ |
JP4473021B2 (ja) | 2004-03-22 | 2010-06-02 | 東芝テック株式会社 | 窒化層形成方法、磁気回路形成部材、アーマチュア、ワイヤドットプリンタヘッド及びワイヤドットプリンタ |
US20050239830A1 (en) * | 2004-04-26 | 2005-10-27 | Vikram Khetani | Methods of diminishing co-abuse potential |
KR20070007196A (ko) * | 2004-04-26 | 2007-01-12 | 테바 파마슈티컬 인더스트리즈 리미티드 | 펙소페나딘 히드로클로라이드의 결정형 및 이의 제조 방법 |
US7498345B2 (en) | 2004-09-17 | 2009-03-03 | Albany Molecular Research, Inc. | Process for production of piperidine derivatives |
US7498443B2 (en) | 2004-09-17 | 2009-03-03 | Albany Molecular Research, Inc. | Process for production of carebastine |
EP1685106A2 (en) * | 2004-09-28 | 2006-08-02 | Teva Pharmaceutical Industries, Inc. | Fexofendadine crystal form and processes for its preparation thereof |
BRPI0517166A (pt) * | 2004-12-09 | 2008-09-30 | Celgene Corp | uso de d-treo-metilfenidato ou um sal do mesmo |
KR20080065704A (ko) | 2005-11-09 | 2008-07-14 | 콤비네이토릭스, 인코포레이티드 | 의학적 이상의 치료 방법들, 조성물들, 및 키트들 |
ES2534589T3 (es) * | 2007-04-13 | 2015-04-24 | Southern Research Institute | Clomipramina como agente antiangiogénico |
US20090076080A1 (en) * | 2007-09-19 | 2009-03-19 | Protia, Llc | Deuterium-enriched fexofenadine |
US20150238473A1 (en) | 2012-09-27 | 2015-08-27 | University Of Rochester | Methods and compositions for treating infection |
NZ735777A (en) * | 2015-03-26 | 2023-03-31 | Jacqueline M Iversen | Methods and compositions to inhibit symptoms associated with veisalgia |
DE102017130361A1 (de) | 2017-12-18 | 2019-07-04 | Lsp Innovative Automotive Systems Gmbh | Statorzahn und Stator mit guter elektrischer Isolierung und gleichzeitig sehr hoher Wärmeleitfähigkeit zur Leistungssteigerung von Elektromotoren |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US880801A (en) † | 1908-03-03 | Harold Larsen | Vibrator. | |
US922890A (en) † | 1907-03-26 | 1909-05-25 | Peder Joergen Hansen | Stream-motor. |
US4254129A (en) † | 1979-04-10 | 1981-03-03 | Richardson-Merrell Inc. | Piperidine derivatives |
US4552899A (en) † | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
US4829064A (en) † | 1987-06-08 | 1989-05-09 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
US4929605A (en) * | 1987-10-07 | 1990-05-29 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol derivatives |
US4996061A (en) † | 1987-10-07 | 1991-02-26 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol-decongestant combination |
HU226561B1 (en) * | 1992-04-10 | 2009-04-28 | Merrell Dow Pharma | Process for preparation 4-diphenylmethyl piperidine derivatives and the novel intermediates thereof |
DE69320952T2 (de) | 1992-05-11 | 1999-05-27 | Merrell Pharma Inc | Verwendung von terfenadin-derivaten als antihistaminika in leberkranken patienten |
HU226242B1 (en) * | 1992-08-03 | 2008-07-28 | Sepracor Inc | Use of terfenadin carboxylic acid, their salt and optically pure isomers for the preparation of pharmaceutical compositions, and pharmaceutical compositions against allergic disorders |
DE69433346T2 (de) * | 1993-06-24 | 2004-09-09 | Albany Molecular Research, Inc. | Herstellung von Verbindungen, die in der Produktion von Piperidin-Derivaten nützlich sind |
AU699559B2 (en) * | 1993-06-25 | 1998-12-10 | Aventisub Ii Inc. | Novel intermediates for the preparation of antihistaminic piperidine derivatives |
CA2128821A1 (en) * | 1993-07-27 | 1995-01-28 | Dilip J. Gole | Freeze-dried pharmaceutical dosage form and process for separation thereof |
CA2128820A1 (en) * | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
WO1995010278A1 (en) * | 1993-10-15 | 1995-04-20 | Hoechst Marion Roussel, Inc. | Treatment of allergic disorders with terfenadine carboxylate |
-
1993
- 1993-08-03 HU HU9500313A patent/HU226242B1/hu unknown
- 1993-08-03 DE DE9320925U patent/DE9320925U1/de not_active Expired - Lifetime
- 1993-08-03 GB GB9502183A patent/GB2284351B/en not_active Revoked
- 1993-08-03 WO PCT/US1993/007260 patent/WO1994003170A1/en active IP Right Grant
- 1993-08-03 AT AT97104837T patent/ATE322899T1/de active
- 1993-08-03 AT AT02006356T patent/ATE363283T1/de active
- 1993-08-03 ES ES97104837T patent/ES2257757T3/es not_active Expired - Lifetime
- 1993-08-03 DK DK93918584T patent/DK0701443T4/da active
- 1993-08-03 EP EP97104837A patent/EP0815860B1/en not_active Revoked
- 1993-08-03 BR BR9306841A patent/BR9306841A/pt not_active Application Discontinuation
- 1993-08-03 AT AT93918584T patent/ATE162399T1/de active
- 1993-08-03 RO RO95-00160A patent/RO116043B1/ro unknown
- 1993-08-03 AU AU47986/93A patent/AU675240B2/en not_active Expired
- 1993-08-03 DK DK02006356T patent/DK1214937T3/da active
- 1993-08-03 ES ES02006356T patent/ES2284740T3/es not_active Expired - Lifetime
- 1993-08-03 KR KR1019950700382A patent/KR950702420A/ko not_active Application Discontinuation
- 1993-08-03 DE DE0701443T patent/DE701443T1/de active Pending
- 1993-08-03 CA CA002141572A patent/CA2141572C/en not_active Expired - Lifetime
- 1993-08-03 ES ES93918584T patent/ES2086270T5/es not_active Expired - Lifetime
- 1993-08-03 EP EP93918584A patent/EP0701443B2/en not_active Expired - Lifetime
- 1993-08-03 EP EP06114048A patent/EP1688142A1/en not_active Withdrawn
- 1993-08-03 JP JP6505499A patent/JP3041954B2/ja not_active Expired - Lifetime
- 1993-08-03 PL PL93307339A patent/PL174373B1/pl unknown
- 1993-08-03 RU RU95107881/14A patent/RU2167657C2/ru active
- 1993-08-03 DK DK97104837T patent/DK0815860T3/da active
- 1993-08-03 SK SK124-95A patent/SK12495A3/sk unknown
- 1993-08-03 DE DE69334008T patent/DE69334008T2/de not_active Expired - Lifetime
- 1993-08-03 DE DE69334145T patent/DE69334145T2/de not_active Expired - Lifetime
- 1993-08-03 PT PT02006356T patent/PT1214937E/pt unknown
- 1993-08-03 PT PT97104837T patent/PT815860E/pt unknown
- 1993-08-03 DE DE69316660T patent/DE69316660T3/de not_active Expired - Lifetime
- 1993-08-03 EP EP02006356A patent/EP1214937B1/en not_active Revoked
-
1994
- 1994-02-02 US US08/191,061 patent/US5375693A/en not_active Expired - Lifetime
-
1995
- 1995-02-01 NO NO19950374A patent/NO310644B1/no not_active IP Right Cessation
- 1995-02-02 FI FI950467A patent/FI950467A/fi unknown
- 1995-02-03 CZ CZ95274A patent/CZ27495A3/cs unknown
-
1996
- 1996-05-31 GR GR960300024T patent/GR960300024T1/el unknown
- 1996-11-19 AU AU71822/96A patent/AU7182296A/en not_active Abandoned
-
1998
- 1998-04-03 GR GR980400714T patent/GR3026530T3/el unknown
-
1999
- 1999-02-25 AU AU18429/99A patent/AU1842999A/en not_active Abandoned
- 1999-10-13 JP JP11291230A patent/JP3037697B2/ja not_active Expired - Lifetime
- 1999-10-13 JP JP29122399A patent/JP3288661B2/ja not_active Expired - Lifetime
- 1999-10-13 JP JP29122899A patent/JP3288662B2/ja not_active Expired - Lifetime
- 1999-10-13 JP JP11291216A patent/JP2000086512A/ja active Pending
- 1999-10-13 JP JP29122099A patent/JP3288660B2/ja not_active Expired - Lifetime
-
2001
- 2001-02-14 GR GR20010400247T patent/GR3035417T3/el unknown
-
2002
- 2002-08-17 HK HK02106014.7A patent/HK1045806B/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950702420A (ko) | 알레르기 질환 치료를 위한 테르페나딘 대사물과 그것의 광학 순수 이성체(terfenadine metabolites and their optically pure isomers for treating allergic disorders) | |
PL172276B1 (pl) | Kompozycja do stosowania zewnetrznego uwalniajaca substancje aromatyczne PL PL PL PL PL PL PL | |
CA2160874C (en) | Nasal aromatic releasing compositions | |
DK310188D0 (da) | Anvendelse af azidothymidin til fremstilling af et farmaceutisk praeparat til anvendelse ved behandling af psoriasis | |
US3629412A (en) | Topical anti-inflammatory agent | |
US5376372A (en) | Analgesic and inflammation-reducing medicament | |
KR970005283A (ko) | 심근경색발생 후의 환자를 처치하기 위한 서트랄린의 용도 | |
WO1999016435A1 (en) | Pharmaceutical compositions containing ricinoleic acid and their use in anti-inflammatory and analgesic therapy | |
JP2752250B2 (ja) | 鎮痛及び抗炎症作用を有する基礎治療剤 | |
JPWO2020176432A5 (ko) | ||
OCHSNER et al. | The Use of Vitamin B, for the Relief of Pain in Varicose Ulcers | |
WO1994000108A1 (en) | Topical aromatic releasing compositions | |
WO2003020274A1 (en) | Treatment of atopic dermatitis | |
KR890001558A (ko) | 공황(恐慌) 장애를 경감시키는 제피론 및 이의 약학적 허용 산부가염 | |
WO2006021166A1 (de) | Kombinationstherapie mit procain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20010829 Effective date: 20021226 Free format text: TRIAL NUMBER: 2001101002882; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20010829 Effective date: 20021226 |
|
J2X1 | Appeal (before the patent court) |
Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL Free format text: TRIAL NUMBER: 2003201000533; APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
J302 | Written judgement (patent court) |
Free format text: JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20030129 Effective date: 20040326 Free format text: TRIAL NUMBER: 2003201000533; JUDGMENT (PATENT COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20030129 Effective date: 20040326 |
|
J2X2 | Appeal (before the supreme court) |
Free format text: APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL Free format text: TRIAL NUMBER: 2004301001199; APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL |
|
J303 | Written judgement (supreme court) |
Free format text: JUDGMENT (SUPREME COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20040420 Effective date: 20040614 Free format text: TRIAL NUMBER: 2004301001199; JUDGMENT (SUPREME COURT) FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20040420 Effective date: 20040614 |